Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study

Autores
Pellegrini, Gretel Gisela; González Chaves, Macarena; Zeni Coronel, Estefania Magali; Avendaño, María Eugenia; Bonanno, Marina Soledad; Zeni, Susana Noemi
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Bone turnover markers are useful to evaluate bone loss and monitor anticatabolic treatments in a short period. The effectiveness of saliva to reflect changes in bone turnover markers during the early administration of different doses of olpadronate (POD) (4 mg or 8 mg/100 g body weight), immediately after Ovariectomy (OVX), was evaluated.Material and Methods: Adult rats (n=10/group) were divided and treated as follows for 45 days: SHAM+Vh; OVX+Vh; OVX+4OPD and OVX+8OPD. To validate the model, Proximal Tibia Bone Mineral Density (PTBMD) change between the beginning and the end of the study. Blood and saliva were collected post-surgery (t=0; t=10; t=20; t=45).Results: PTBMD decrease in OVX+Vh was partially prevented by 4OPD and avoided by 8OPD. Salivary and serum β-CrossLaps (CTX) in SHAM+Vh remained without changes and increased in OVX+Vh (p<0.05); Bone-Specific Alkaline Phosphatase (B-ALP) increased in OVX+Vh versus SHAM+Vh reaching signicance at t=20 (p< 0.05). A dose-dependent response was observed insalivary and serum CTX and B-ALP by OPD treatment (p<0.05). CTX was lower in OVX+8OPD versus OVX+4OPD from t=10 in serum samples and from t=20 in salivary samples (p<0.05) while B-ALP reached lower levels at t=45 (p<0.05).Conclusion: Although further clinical studies are needed, our results suggest that CTX and B-ALP in saliva decreased by Bisphosphonate (BP) therapy in a dose dependent manner. Therefore, saliva would be a suitable tool for evaluating changes in bone turnover due to BP therapy in the early stage of estrogen withdrawal.
Fil: Pellegrini, Gretel Gisela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Columbia University. Center For Science And Society.; Estados Unidos
Fil: González Chaves, Macarena. Universidad de Buenos Aires; Argentina
Fil: Zeni Coronel, Estefania Magali. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
Fil: Avendaño, María Eugenia. Universidad Nacional de Cuyo; Argentina
Fil: Bonanno, Marina Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
Fil: Zeni, Susana Noemi. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
Materia
BONE TURNOVER MARKERS
OSTEOPOROSIS
SALIVA
ESTROGEN WITHDRAWAL
BISPHOSPHONATE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/135236

id CONICETDig_8a326c3a43e2817a903ce928540c7fb2
oai_identifier_str oai:ri.conicet.gov.ar:11336/135236
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental StudyPellegrini, Gretel GiselaGonzález Chaves, MacarenaZeni Coronel, Estefania MagaliAvendaño, María EugeniaBonanno, Marina SoledadZeni, Susana NoemiBONE TURNOVER MARKERSOSTEOPOROSISSALIVAESTROGEN WITHDRAWALBISPHOSPHONATEhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Background: Bone turnover markers are useful to evaluate bone loss and monitor anticatabolic treatments in a short period. The effectiveness of saliva to reflect changes in bone turnover markers during the early administration of different doses of olpadronate (POD) (4 mg or 8 mg/100 g body weight), immediately after Ovariectomy (OVX), was evaluated.Material and Methods: Adult rats (n=10/group) were divided and treated as follows for 45 days: SHAM+Vh; OVX+Vh; OVX+4OPD and OVX+8OPD. To validate the model, Proximal Tibia Bone Mineral Density (PTBMD) change between the beginning and the end of the study. Blood and saliva were collected post-surgery (t=0; t=10; t=20; t=45).Results: PTBMD decrease in OVX+Vh was partially prevented by 4OPD and avoided by 8OPD. Salivary and serum β-CrossLaps (CTX) in SHAM+Vh remained without changes and increased in OVX+Vh (p<0.05); Bone-Specific Alkaline Phosphatase (B-ALP) increased in OVX+Vh versus SHAM+Vh reaching signicance at t=20 (p< 0.05). A dose-dependent response was observed insalivary and serum CTX and B-ALP by OPD treatment (p<0.05). CTX was lower in OVX+8OPD versus OVX+4OPD from t=10 in serum samples and from t=20 in salivary samples (p<0.05) while B-ALP reached lower levels at t=45 (p<0.05).Conclusion: Although further clinical studies are needed, our results suggest that CTX and B-ALP in saliva decreased by Bisphosphonate (BP) therapy in a dose dependent manner. Therefore, saliva would be a suitable tool for evaluating changes in bone turnover due to BP therapy in the early stage of estrogen withdrawal.Fil: Pellegrini, Gretel Gisela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Columbia University. Center For Science And Society.; Estados UnidosFil: González Chaves, Macarena. Universidad de Buenos Aires; ArgentinaFil: Zeni Coronel, Estefania Magali. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaFil: Avendaño, María Eugenia. Universidad Nacional de Cuyo; ArgentinaFil: Bonanno, Marina Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaFil: Zeni, Susana Noemi. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaAustin Publishing Group2020-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/135236Pellegrini, Gretel Gisela; González Chaves, Macarena; Zeni Coronel, Estefania Magali; Avendaño, María Eugenia; Bonanno, Marina Soledad; et al.; Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study; Austin Publishing Group; Austin Journal of Dentistry; 7; 12-2020; 1-52381-9189CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://austinpublishinggroup.com/dentistry/download.php?file=fulltext/jd-v7-id1145.pdfinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:43:32Zoai:ri.conicet.gov.ar:11336/135236instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:43:33.025CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
title Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
spellingShingle Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
Pellegrini, Gretel Gisela
BONE TURNOVER MARKERS
OSTEOPOROSIS
SALIVA
ESTROGEN WITHDRAWAL
BISPHOSPHONATE
title_short Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
title_full Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
title_fullStr Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
title_full_unstemmed Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
title_sort Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study
dc.creator.none.fl_str_mv Pellegrini, Gretel Gisela
González Chaves, Macarena
Zeni Coronel, Estefania Magali
Avendaño, María Eugenia
Bonanno, Marina Soledad
Zeni, Susana Noemi
author Pellegrini, Gretel Gisela
author_facet Pellegrini, Gretel Gisela
González Chaves, Macarena
Zeni Coronel, Estefania Magali
Avendaño, María Eugenia
Bonanno, Marina Soledad
Zeni, Susana Noemi
author_role author
author2 González Chaves, Macarena
Zeni Coronel, Estefania Magali
Avendaño, María Eugenia
Bonanno, Marina Soledad
Zeni, Susana Noemi
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv BONE TURNOVER MARKERS
OSTEOPOROSIS
SALIVA
ESTROGEN WITHDRAWAL
BISPHOSPHONATE
topic BONE TURNOVER MARKERS
OSTEOPOROSIS
SALIVA
ESTROGEN WITHDRAWAL
BISPHOSPHONATE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Bone turnover markers are useful to evaluate bone loss and monitor anticatabolic treatments in a short period. The effectiveness of saliva to reflect changes in bone turnover markers during the early administration of different doses of olpadronate (POD) (4 mg or 8 mg/100 g body weight), immediately after Ovariectomy (OVX), was evaluated.Material and Methods: Adult rats (n=10/group) were divided and treated as follows for 45 days: SHAM+Vh; OVX+Vh; OVX+4OPD and OVX+8OPD. To validate the model, Proximal Tibia Bone Mineral Density (PTBMD) change between the beginning and the end of the study. Blood and saliva were collected post-surgery (t=0; t=10; t=20; t=45).Results: PTBMD decrease in OVX+Vh was partially prevented by 4OPD and avoided by 8OPD. Salivary and serum β-CrossLaps (CTX) in SHAM+Vh remained without changes and increased in OVX+Vh (p<0.05); Bone-Specific Alkaline Phosphatase (B-ALP) increased in OVX+Vh versus SHAM+Vh reaching signicance at t=20 (p< 0.05). A dose-dependent response was observed insalivary and serum CTX and B-ALP by OPD treatment (p<0.05). CTX was lower in OVX+8OPD versus OVX+4OPD from t=10 in serum samples and from t=20 in salivary samples (p<0.05) while B-ALP reached lower levels at t=45 (p<0.05).Conclusion: Although further clinical studies are needed, our results suggest that CTX and B-ALP in saliva decreased by Bisphosphonate (BP) therapy in a dose dependent manner. Therefore, saliva would be a suitable tool for evaluating changes in bone turnover due to BP therapy in the early stage of estrogen withdrawal.
Fil: Pellegrini, Gretel Gisela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Columbia University. Center For Science And Society.; Estados Unidos
Fil: González Chaves, Macarena. Universidad de Buenos Aires; Argentina
Fil: Zeni Coronel, Estefania Magali. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
Fil: Avendaño, María Eugenia. Universidad Nacional de Cuyo; Argentina
Fil: Bonanno, Marina Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
Fil: Zeni, Susana Noemi. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
description Background: Bone turnover markers are useful to evaluate bone loss and monitor anticatabolic treatments in a short period. The effectiveness of saliva to reflect changes in bone turnover markers during the early administration of different doses of olpadronate (POD) (4 mg or 8 mg/100 g body weight), immediately after Ovariectomy (OVX), was evaluated.Material and Methods: Adult rats (n=10/group) were divided and treated as follows for 45 days: SHAM+Vh; OVX+Vh; OVX+4OPD and OVX+8OPD. To validate the model, Proximal Tibia Bone Mineral Density (PTBMD) change between the beginning and the end of the study. Blood and saliva were collected post-surgery (t=0; t=10; t=20; t=45).Results: PTBMD decrease in OVX+Vh was partially prevented by 4OPD and avoided by 8OPD. Salivary and serum β-CrossLaps (CTX) in SHAM+Vh remained without changes and increased in OVX+Vh (p<0.05); Bone-Specific Alkaline Phosphatase (B-ALP) increased in OVX+Vh versus SHAM+Vh reaching signicance at t=20 (p< 0.05). A dose-dependent response was observed insalivary and serum CTX and B-ALP by OPD treatment (p<0.05). CTX was lower in OVX+8OPD versus OVX+4OPD from t=10 in serum samples and from t=20 in salivary samples (p<0.05) while B-ALP reached lower levels at t=45 (p<0.05).Conclusion: Although further clinical studies are needed, our results suggest that CTX and B-ALP in saliva decreased by Bisphosphonate (BP) therapy in a dose dependent manner. Therefore, saliva would be a suitable tool for evaluating changes in bone turnover due to BP therapy in the early stage of estrogen withdrawal.
publishDate 2020
dc.date.none.fl_str_mv 2020-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/135236
Pellegrini, Gretel Gisela; González Chaves, Macarena; Zeni Coronel, Estefania Magali; Avendaño, María Eugenia; Bonanno, Marina Soledad; et al.; Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study; Austin Publishing Group; Austin Journal of Dentistry; 7; 12-2020; 1-5
2381-9189
CONICET Digital
CONICET
url http://hdl.handle.net/11336/135236
identifier_str_mv Pellegrini, Gretel Gisela; González Chaves, Macarena; Zeni Coronel, Estefania Magali; Avendaño, María Eugenia; Bonanno, Marina Soledad; et al.; Levels of Bone Turnover in Saliva Correlated with Antirresortive Treatment: Experimental Study; Austin Publishing Group; Austin Journal of Dentistry; 7; 12-2020; 1-5
2381-9189
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://austinpublishinggroup.com/dentistry/download.php?file=fulltext/jd-v7-id1145.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Austin Publishing Group
publisher.none.fl_str_mv Austin Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268609259241472
score 13.13397